

Review

Evaluation and Management of Mild Hyponatremia in Stable Hospitalized Patients

Hamed Saeed Alghamdi^{1*}, Ammar Ahmad Alammar², Waad Abdullah Qaeed³, Malath Ahmed Bisharah⁴, Wael Saad Saeed⁵, Effat Abdullah Neyazi⁴, Sara Ali Aljassim⁶, Noor Mohammed Abdulrahim⁷, Abdulkhaliq Hadi Asiri⁸, Hussain Ziad Melyani⁴, Basmah Mohammed Aljohani⁹

¹ Department of Internal Medicine, King Abdulaziz Hospital, Jeddah, Saudi Arabia

² College of Medicine, Sulaiman Al Rajhi University, Al-Qassim, Saudi Arabia

³ Department of Pharmacy, Al Ahly Hospital, Khamis Mushait, Saudi Arabia

⁴ College of Medicine, Umm Al Qura University, Mecca, Saudi Arabia

⁵ Department of Emergency Medicine, Al Majaradah Hospital, Abha, Saudi Arabia

⁶ Department of Internal Medicine, Ministry of Health, Al-Ahsa, Saudi Arabia

⁷ College of Medicine, Batterjee Medical College, Jeddah, Saudi Arabia

⁸ College of Medicine, King Khalid University, Abha, Saudi Arabia

⁹ Department of Extended Care, King Fahad General Hospital, Jeddah, Saudi Arabia

Correspondence should be addressed **Hamed Saeed Alghamdi**, Department of Internal Medicine, King Abdulaziz Hospital, Jeddah, Saudi Arabia, Email: alghamdi982@gmail.com

Copyright © 2025 **Hamed Saeed Alghamdi**. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 06 December 2025, Accepted: 19 January 2026, Published: 22 January 2026.

Abstract

Mild hyponatremia, defined as a serum sodium concentration between 130 and 134 mmol/L, is a frequent finding among stable hospitalized patients. Despite being often overlooked, accumulating evidence links this condition to adverse outcomes, including impaired cognition, gait instability, prolonged hospitalization, and increased mortality. The subtle nature of symptoms contributes to underrecognition, especially in older adults, where the physiological impact may be more pronounced. Even small deviations from normal sodium levels can compromise clinical recovery and increase vulnerability to complications such as falls and fractures. Evaluation of mild hyponatremia remains inconsistent across clinical settings. Urine studies and fluid status assessments are frequently omitted or delayed, and treatment is often initiated without a clear understanding of the underlying cause. Guidelines exist but are not always integrated into routine hospital workflows, resulting in wide variations in practice. Volume status misclassification, inadequate monitoring, and lack of targeted diagnostic efforts continue to pose challenges. Limited education around the clinical implications of mild hyponatremia further contributes to therapeutic hesitation or inappropriate correction. Management strategies include fluid restriction, medication review, and in selected cases, pharmacologic intervention using vasopressin receptor antagonists or hypertonic saline. However, concerns about overcorrection, treatment risks, and access barriers often lead to conservative approaches that may not address the root cause. Despite these challenges, correction of mild hyponatremia has been associated with improved physical function and reduced hospital readmissions. Enhancing clinician awareness, standardizing evaluation protocols, and addressing system-level barriers are necessary steps to improve the management and outcomes of this often-underestimated condition.

Keywords: hyponatremia, hospitalized patients, fluid balance, vasopressin antagonists, electrolyte disorders

Introduction

Hyponatremia, defined as a serum sodium concentration below 135 mmol/L, is the most common electrolyte disturbance observed in hospitalized patients. Even mild reductions in sodium levels, often dismissed as clinically insignificant, are increasingly recognized for their potential impact on patient outcomes. Mild hyponatremia, typically ranging from 130 to 134 mmol/L, can be found in a broad spectrum of clinical contexts and has been associated with subtle but important effects on cognition, gait stability, and quality of life (1). These effects are particularly relevant in older adults, where mild hyponatremia may increase the risk of falls, fractures, and functional decline, despite the absence of overt symptoms.

The pathophysiology of hyponatremia in stable hospitalized patients is multifactorial. It may reflect an imbalance in water homeostasis due to non-osmotic vasopressin release, impaired renal water excretion, or iatrogenic factors such as hypotonic fluid administration. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) remains one of the leading causes in euvoletic hospitalized individuals. Importantly, even mild cases require thoughtful evaluation to distinguish between dilutional and depletion states, as treatment strategies differ significantly depending on the underlying etiology. Early recognition of contributing factors is crucial to avoid progression and prevent complications associated with overly rapid correction or inappropriate fluid management (2).

Management strategies for mild hyponatremia vary widely in clinical practice, often influenced by physician preference, institutional protocols, or underestimation of its clinical relevance. While some advocate for conservative approaches such as fluid restriction or observation in stable patients, others recommend targeted pharmacologic therapy or discontinuation of offending agents. Recent guidelines emphasize individualized management based on symptom severity, chronicity, and underlying cause. However, inconsistent

application of these recommendations can lead to under-treatment or overtreatment, each carrying its own risks (3). This underscores the need for a balanced approach guided by clear diagnostic criteria and patient-specific considerations.

Emerging data suggest that even mild chronic hyponatremia may carry prognostic significance, including associations with increased length of hospital stay, readmission rates, and all-cause mortality. These associations persist even after adjusting for comorbidities, suggesting that mild hyponatremia is not merely a marker of illness severity but may be a modifiable risk factor (4). In this review, we will discuss the evaluation and management of mild hyponatremia in stable hospitalized patients.

Review

Mild hyponatremia in stable hospitalized patients is often underappreciated, despite growing evidence linking it to significant clinical consequences. While traditionally considered benign, studies have demonstrated that even small reductions in serum sodium can lead to impairments in attention, gait, and balance, increasing the likelihood of falls and associated complications, especially in elderly populations (5). These subtle effects can contribute to prolonged hospitalization, delayed rehabilitation, and increased healthcare costs. Therefore, recognizing and managing mild hyponatremia may have a meaningful impact on overall patient recovery.

The optimal management of mild hyponatremia remains a subject of clinical debate. Although fluid restriction is frequently used as a first-line approach, it is often poorly tolerated and may be ineffective in certain patients, particularly those with SIADH. Pharmacologic options such as vasopressin receptor antagonists have shown promise in correcting sodium levels, but their use must be weighed against potential adverse effects and cost considerations (6). Furthermore, accurate etiological classification is essential before initiating any intervention, as mismanagement can lead to overcorrection or worsening of the underlying condition. This highlights the importance of a structured and

individualized approach to the evaluation and treatment of hyponatremia in stable hospitalized patients.

Clinical Relevance and Prognostic Implications of Mild Hyponatremia

Mild hyponatremia, although frequently regarded as a laboratory anomaly with limited clinical weight, has been repeatedly associated with unfavorable outcomes across various patient populations. Even when asymptomatic, serum sodium concentrations in the range of 130 to 134 mmol/L correlate with measurable impairments in cognitive function, reaction time, and postural stability. These impairments may not be obvious during routine clinical evaluations, especially in hospitalized patients who are medically stable, yet they can quietly increase susceptibility to falls and injuries, particularly in older adults. The subtle but pervasive impact on neurocognitive function often goes unrecognized, despite studies demonstrating clear physiological consequences of chronic hyponatremia, including cerebral edema and altered neuronal excitability (7).

Evidence from large observational cohorts indicates that mild hyponatremia is linked with longer hospital stays, higher rates of institutional discharge, and increased readmission risk. The correlation between even modest sodium derangements and extended length of hospitalization suggests a wider systemic burden that may not be immediately traceable to electrolyte levels alone. In patients with heart failure, cirrhosis, and pneumonia, mild hyponatremia has been identified as an independent predictor of mortality, suggesting that it serves as more than a secondary marker of illness severity. Instead, it may contribute actively to poorer outcomes through its effects on immune function, cardiovascular stability, and medication sensitivity (8). The consistent presence of hyponatremia across diverse conditions indicates a shared pathway involving impaired water clearance and hormonal dysregulation, which can amplify patient vulnerability in seemingly stable scenarios.

Hospitalized individuals with mild hyponatremia often receive less urgent evaluation and treatment compared to those with moderate or severe sodium deficits. This discrepancy may arise from the common misconception that values just below the normal threshold are clinically insignificant. However, emerging research points to a graded relationship between sodium levels and prognosis. In a study of over 50,000 hospitalized patients, each 1 mmol/L decrease in serum sodium below 135 mmol/L was associated with a proportional increase in adverse outcomes, including in-hospital mortality (9). These associations persisted after adjusting for comorbid conditions and baseline functional status, reinforcing the idea that sodium imbalance, even when mild, represents a modifiable risk factor. The absence of acute neurological symptoms in many patients should not be mistaken for safety, as chronic hyponatremia exerts its effects gradually, leading to cumulative harm over time.

In addition to physical and cognitive outcomes, mild hyponatremia appears to impact healthcare resource use and treatment decisions. For instance, its presence has been shown to influence the prescription of diuretics, fluid therapy, and diagnostic workups, often leading to changes in clinical plans not based on comprehensive etiologic assessment. Patients with mild hyponatremia are also more likely to undergo unnecessary restrictions or interventions in an attempt to normalize values, despite lack of clear benefit in certain subgroups. This reflects a broader uncertainty among clinicians regarding the threshold at which treatment becomes necessary. A nuanced understanding of patient context, chronicity of hyponatremia, and its trajectory during hospitalization is critical for avoiding both overtreatment and under-recognition (10).

Therapeutic Approaches and Outcome Considerations

Managing mild hyponatremia in stable hospitalized patients requires balancing the correction of serum sodium with patient safety and overall clinical goals. Often, the decision to intervene depends not only on sodium concentration but also on the patient's volume status, symptom presentation, and

underlying etiology. While some cases benefit from simple discontinuation of contributing medications or adjustment of fluid intake, others require more targeted therapies. Euvolemic patients with syndrome of inappropriate antidiuretic hormone secretion, for example, often respond to fluid restriction, though adherence and effectiveness can vary widely. In these scenarios, fluid restriction can be burdensome, especially for older adults who may already have reduced oral intake or competing nutritional needs (11).

Vasopressin receptor antagonists, such as tolvaptan, represent a pharmacological alternative, offering aquaretic correction without significant changes in electrolytes or renal function. These agents promote free water excretion, increasing serum sodium in cases resistant to conservative therapy. Randomized trials have demonstrated their efficacy in raising sodium levels over short periods, but concerns remain about cost, hepatic safety, and long-term outcomes. Tolvaptan has been associated with rapid correction if not carefully monitored, and its use is often reserved for selected patients who do not respond to non-pharmacologic measures (12).

Hypertonic saline is typically avoided in mild cases unless there is evidence of neurologic compromise or when sodium is trending downward despite other interventions. The risk of overly rapid correction remains the central concern, as this may precipitate osmotic demyelination syndrome, a rare but serious complication. Clinicians often hesitate to initiate hypertonic saline in stable patients due to this risk, leading to delays in treatment or reliance on less effective methods. Newer protocols using controlled low-dose infusions have been proposed to minimize such risks while offering better control over serum sodium increments (13, 14).

Outcomes related to mild hyponatremia treatment are influenced by both the choice of therapy and how well underlying causes are addressed. Correction alone does not guarantee improved prognosis unless reversible contributors such as medications, infections, or endocrine disorders are also managed. Patients who achieve normonatremia during hospitalization tend to have reduced lengths

of stay and lower readmission rates, although the causal relationship is still debated. Observational data suggest that successful resolution of hyponatremia correlates with better physical function scores and fewer in-hospital complications, especially among older adults and those recovering from surgery or acute illness (15).

Barriers to Optimal Evaluation and Treatment

Efforts to evaluate and manage mild hyponatremia in stable hospitalized patients often fall short due to a complex combination of clinical inertia, system-level constraints, and gaps in knowledge translation. Despite the availability of diagnostic algorithms and clinical practice guidelines, consistent application remains rare outside of nephrology or critical care settings. Many general practitioners and hospitalists are unfamiliar with the nuanced differentiation between hypovolemic, euvolemic, and hypervolemic hyponatremia, leading to a pattern of reactive, rather than structured, decision-making. Even basic diagnostic steps are often skipped, which limits the ability to identify the underlying etiology and delays appropriate interventions (16).

Time pressure, competing clinical demands, and lack of immediate access to nephrology consultation all contribute to insufficient evaluation. Mild hyponatremia is frequently overshadowed by more acute medical concerns during hospitalization, particularly in patients admitted for unrelated primary diagnoses. When sodium levels hover close to the normal range, the perceived urgency to act is low, and many teams adopt a watch-and-wait approach. However, this underestimates the potential harm of chronic mild hyponatremia, especially in older or functionally impaired patients. Without structured prompts or alerts integrated into electronic health records, it becomes easier for clinicians to ignore subtle but persistent electrolyte derangements (17).

Education also plays a major role in shaping clinical behavior. Curricula in internal medicine often focus more intensively on emergency management of severe hyponatremia than on subtler presentations. This leaves trainees underprepared to navigate the full spectrum of the condition. Additionally, there is

considerable variation in institutional practices regarding sodium monitoring frequency, fluid management protocols, and criteria for initiating treatment. Some hospitals lack formal guidelines altogether, relying on clinician judgment, which introduces inconsistency across services and departments. When evidence-based protocols are absent or difficult to access, overcorrection and undertreatment both become more likely, particularly in patients transitioning between units or care teams (18).

Therapeutic decisions are further complicated by limited access to certain interventions, particularly in community or resource-limited settings. Medications like vasopressin antagonists are not always available or approved, and even when they are, their use is often restricted due to cost or regulatory controls. Laboratory turnaround time for essential tests can also delay diagnosis. In hospitals where urine electrolyte panels take more than a few hours to process, the practical utility of these results decreases. Clinicians may opt to proceed based on incomplete data or fall back on empirical therapy. These delays not only hinder timely intervention but also diminish opportunities to track patient progress using objective markers. In such environments, the management of mild hyponatremia becomes vulnerable to guesswork, shaped more by habit and logistics than by patient-specific factors or evolving evidence (19).

Conclusion

Mild hyponatremia in stable hospitalized patients demands more attention than it typically receives. Its subtle clinical impact and associations with poor outcomes make early recognition and proper management essential. Inconsistent evaluation and therapeutic practices continue to limit progress in care quality. A more standardized, evidence-informed approach could significantly improve patient safety and recovery.

Disclosure

Conflict of interest

There is no conflict of interest.

Funding

No funding.

Ethical consideration

Non applicable.

Data availability

All data is available within the manuscript.

Author contribution

All authors contributed to conceptualizing, data drafting, collection and final writing of the manuscript.

References

1. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. *The American journal of medicine*. 2006;119(1):71. e1-. e8.
2. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. *The American journal of medicine*. 2013;126(10):S1-S42.
3. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Nephrology Dialysis Transplantation*. 2014;29(suppl_2):i1-i39.
4. Corona G, Giuliani C, Parenti G, Norello D, Verbalis JG, Forti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. *PloS one*. 2013;8(12):e80451.
5. Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: compilation of the guidelines. *Journal of the American Society of Nephrology*. 2017;28(5):1340-9.
6. Adrogué HJ, Madias NE. The syndrome of inappropriate antidiuresis. *New England Journal of Medicine*. 2023;389(16):1499-509.

7. Adrogué HJ, Madias NE. Hyponatremia. *New England Journal of Medicine*. 2000;342(21):1581-9.
8. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. *Archives of internal medicine*. 2010;170(3):294-302.
9. Funk G-C, Lindner G, Druml W, Metnitz B, Schwarz C, Bauer P, et al. Incidence and prognosis of dysnatremias present on ICU admission. *Intensive care medicine*. 2010;36(2):304-11.
10. Clayton J, Le Jeune I, Hall I. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. *Journal of the Association of Physicians*. 2006;99(8):505-11.
11. Berl T. Impact of solute intake on urine flow and water excretion. *Journal of the American Society of Nephrology*. 2008;19(6):1076-8.
12. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. *New England Journal of Medicine*. 2006;355(20):2099-112.
13. Chifu I, Gerstl A, Lengenfelder B, Schmitt D, Nagler N, Fassnacht M, et al. Treatment of symptomatic hyponatremia with hypertonic saline: a real-life observational study. *European journal of endocrinology*. 2021;184(5):647-55.
14. Nzerue CM, Baffoe-Bonnie H, You W, Falana B, Dai S. Predictors of outcome in hospitalized patients with severe hyponatremia. *Journal of the National Medical Association*. 2003;95(5):335.
15. Corona G, Giuliani C, Verbalis JG, Forti G, Maggi M, Peri A. Hyponatremia improvement is associated with a reduced risk of mortality: evidence from a meta-analysis. *PloS one*. 2015;10(4):e0124105.
16. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. *The American journal of medicine*. 2006;119(7):S30-S5.
17. Cohen DM, Ellison DH. Evaluating hyponatremia. *JAMA*. 2015;313(12):1260-1.
18. Mohan S, Gu S, Parikh A, Radhakrishnan J. Prevalence of hyponatremia and association with mortality: results from NHANES. *The American journal of medicine*. 2013;126(12):1127-37. e1.
19. Braun MM, Barstow CH, Pyzocha NJ. Diagnosis and management of sodium disorders: hyponatremia and hypernatremia. *American family physician*. 2015;91(5):299-307.